Page 1

Medios sets out Ambition 2031 : € 3.1 billion revenue and a doubling of EBITDA adjusted Medios AG / Key word ( s ) : Capital Markets Day Medios sets out Ambition 2031 : € 3.1 billion revenue and a doubling of EBITDA adjusted 29.09.2026 / 07:31 CET / CEST The issuer is solely responsible for the content of this announcement . PRESS RELEASE Medios sets out Ambition 2031 : € 3.1 billion revenue and a doubling of EBITDA adjusted • “ Medios Next Level " strategy : Repositioning from Specialty Pharma to Pharma Services • Focus on the core business models with two operating segments : Specialty Pharma Supply and Compounding • Profitable growth in both segments : around 5 % organic revenue CAGR up to 2031 • supported by operational excellence Disciplined capital allocation : prudent 2.0x net debt / EBITDA ceiling as internal target not to be exceeded providing high flexibility for selective M & A in Compounding as well as potential dividend or share buybacks for our shareholders • Ambition 2031 : around € 3.1 billion revenue ( + 50 % vs. 2025 ) with EBITDA adjusted to double to around € 170 million Berlin , September 29 , 2026 - Medios Group ( " Medios ” , ISIN : DE000A1MMCC8 ) today presents its " Medios Next Level " strategy and Ambition 2031 at its Capital Markets Day in Breda , the Netherlands . The strategy repositions Medios from a Specialty Pharma company to a focused Pharma Services Group organized around two operating segments : Specialty Pharma Supply and Compounding . It is built on four pillars - operational excellence , organic growth , international expansion in Compounding , as well as selective and accretive M & A . The objectives are profitable growth , strong cash generation and a higher - quality earnings mix . By 2031 , Medios aims to reach approximately € 3.1 billion in Group revenue , while EBITDA adjusted is expected to double to around € 170 million . Thomas Meier , CEO of Medios AG : " With our “ Medios Next Level " strategy we are leveraging our strong market position for higher - quality growth . We are focusing on our core business and giving each business a clear mandate . Specialty Pharma Supply provides resilience , stable margin profiles as well as cash , and focused investment in Compounding strengthens our higher- margin core . This is a strategy of evolution – built on a track record of growth and executed with discipline . " -